Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity.

[1]  Sanjay G. Patel,et al.  Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. , 2015, European urology.

[2]  P. Hegde,et al.  MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer , 2014, Nature.

[3]  A. Jemal,et al.  Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. , 2014, International journal of radiation oncology, biology, physics.

[4]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[5]  J. Edwards,et al.  The interrelationships between Src, Cav-1 and RhoGD12 in transitional cell carcinoma of the bladder , 2012, British Journal of Cancer.

[6]  R. Dahiya,et al.  Curcumin Modulates MicroRNA-203–Mediated Regulation of the Src-Akt Axis in Bladder Cancer , 2011, Cancer Prevention Research.

[7]  M. Parmar,et al.  International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  H. Frierson,et al.  Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. , 2011, Cancer research.

[9]  M. Eliasziw,et al.  Referral and treatment rates of neoadjuvant chemotherapy in muscle-invasive bladder cancer before and after publication of a clinical practice guideline. , 2010, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

[10]  G. Sonpavde,et al.  Dasatinib Is Preclinically Active against Src-Overexpressing Human Transitional Cell Carcinoma of the Urothelium with Activated Src Signaling , 2010, Molecular Cancer Therapeutics.

[11]  H. Grossman,et al.  Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy , 2009, Cancer.

[12]  H. Frierson,et al.  Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function , 2009, Proceedings of the National Academy of Sciences.

[13]  U. Capitanio,et al.  Multi-institutional validation of the predictive value of Ki-67 labeling index in patients with urinary bladder cancer. , 2009, Journal of the National Cancer Institute.

[14]  E. Klein,et al.  Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. , 2008, Journal of Urology.

[15]  M. Steinberg.  Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. , 2007, Clinical therapeutics.

[16]  P. Carroll,et al.  Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. , 2007, The Journal of urology.

[17]  C. Roehrborn,et al.  Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. , 2007, The Lancet. Oncology.

[18]  A. Vickers,et al.  Impact of renal impairment on eligibility for adjuvant cisplatin‐based chemotherapy in patients with urothelial carcinoma of the bladder , 2006, Cancer.

[19]  C. Vale.  Neoadjuvant Chemotherapy in Invasive Bladder Cancer: Update of a Systematic Review and Meta-Analysis of Individual Patient Data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration , 2005 .

[20]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[21]  M. Poupon,et al.  Src kinase contributes to the metastatic spread of carcinoma cells , 2002, Oncogene.

[22]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  T. Yeatman,et al.  Elevated c-Src protein expression is an early event in colonic neoplasia. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[24]  I. Summerhayes,et al.  Elevated expression of pp60c-src in low grade human bladder carcinoma. , 1992, Cancer research.

[25]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.